On the recordApril 4, 2022
key among these challenges is reaching agreement with regulators about determining the appropriate efficacy endpoints to support approval of innovative medicines for rare diseases.
Source
congress.govEditor's note · Context
Emphasizes the need for regulatory agreement on efficacy endpoints for rare disease drug approvals.
Share
More from Bob Casey
Aug 7, 2024
Addressing these challenges is essential to our State's and our country's success, and we are grateful for Senator Casey's work to shine a light on the urgent need to invest in care.
Jul 31, 2024
I rise just for 1 minute to talk about Judge Saporito. Joe Saporito is someone I have known for decades. He is someone who serves currently and has for the last 9 years as a magistrate judge in the U.S. District Court for the Middle…
Aug 6, 2024
These are just a few, Senator Casey of the ways in which what we're hearing here is individual stories ladder up.
Other voices in this conversation
